If you want an idea of the kind of biotech M&A deals to expect in H2, look at the recent spate of buyouts.
Endpoints News talked with a pharma investment banker, an experienced dealmaker, a finance professor at MIT and a top analyst to find out what’s center stage these days in the M&A scene, as the bear market mauls biotech stocks and erases follow-on opportunities.
The trend of acquiring late-stage biotech companies is expected to continue into the second half of the year, sources told Endpoints. But while there are signs of hope for a quickened pace of M&A — Bristol Myers Squibb’s announcement it would acquire clinical-stage precision oncology company Turning Point Therapeutics for a 122% premium over the previous closing price made some question if the bear market may finally be over — there aren’t any guarantees.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 143,600+ biopharma pros reading Endpoints daily — and it’s free.
SIGN UP
LOG IN
